← Leaderboards
Deepak Cyril D'souza
Va Connecticut Healthcare System
$19,528,669
Attributed
$23,564,410
Total exposure
24
Grants
19
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.1M · FY2007–25$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$23,564,410 · 22
VA$0 · 2
By mechanism
U01$10,356,374 · 2
R01$7,181,363 · 5
R21$6,026,673 · 15
I01$0 · 2
Top collaborators
- Rajiv Radhakrishnan6 shared
- Anahita Bassir Nia4 shared
- Joel Gelernter4 shared
- Donald Douglas Mcgeary4 shared
- Kelly P Cosgrove2 shared
- Ashley Schnakenberg Martin2 shared
- Mohini Ranganathan2 shared
- Patrick D Skosnik2 shared
Most similar at Va Connecticut Healthcare System
Same institution · by research overlap
- Donald Douglas McGeary$2,862,647
- James Warren Murrough$11,441,785
Others in their field
Top investigators on “Cannabinoids”
- Alexandros Makriyannis · University Of Connecticut Storrs$39,379,878
- Yasmin L Hurd · Icahn School Of Medicine At Mount Sinai$31,535,958
- Daniele Piomelli · University Of California Irvine$17,726,721
- Kenneth P. Mackie · Queen'S Medical Center$16,568,516
- Jenny L. Wiley · Virginia Commonwealth University$14,895,613
- Margaret Haney · New York State Psychiatric Institute$12,928,249
Research focus
CannabinoidsCannabisPharmaceutical PreparationsDouble-Blind MethodRandomizedBrainTetrahydrocannabinolChronicMemoryDoseAcuteAttentionReportingMarijuana UseAnimalsPlacebosSchizophreniaResponseAgonistAbstinenceElectroencephalographyCognitiveCognitive FunctionIn Vivo
Grant awards (67)
Genetic Basis of the Risk and Consequences of Cannabis Exposure in Humans$554,494
R01 · FY2025 · DA · contact PI
Do hippocampal synaptic density deficits in cannabis use disorder improve following abstinence?$514,058
R01 · FY2025 · DA · contact PI
Acute effects of THC in older adults$209,375
R21 · FY2025 · DA · contact PI
Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain.$0
I01 · FY2025 · VA · contact PI
Do hippocampal synaptic density deficits in cannabis use disorder improve following abstinence?$597,469
R01 · FY2024 · DA · contact PI
Genetic Basis of the Risk and Consequences of Cannabis Exposure in Humans$564,257
R01 · FY2024 · DA · contact PI
Acute effects of THC in older adults$251,250
R21 · FY2024 · DA · contact PI
Genetic Basis of the Risk and Consequences of Cannabis Exposure in Humans$158,513
R01 · FY2024 · DA · contact PI
The potential therapeutic effects of N, N-dimethyltryptamine (DMT) on alcohol use disorder (AUD)$155,444
R21 · FY2024 · AA
Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain.$0
I01 · FY2024 · VA · contact PI
Genetic Basis of the Risk and Consequences of Cannabis Exposure in Humans$589,050
R01 · FY2023 · DA · contact PI
Do hippocampal synaptic density deficits in cannabis use disorder improve following abstinence?$586,734
R01 · FY2023 · DA · contact PI
Endocannabinoid System Alterations in Opioid Use Disorder (OUD)$251,250
R21 · FY2023 · DA
The potential therapeutic effects of N, N-dimethyltryptamine (DMT) on alcohol use disorder (AUD)$188,169
R21 · FY2023 · AA
Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain.$0
I01 · FY2023 · VA · contact PI
Do hippocampal synaptic density deficits in cannabis use disorder improve following abstinence?$579,972
R01 · FY2022 · DA · contact PI
Preliminary studies of muscarinic M1 receptor availability and cognition in schizophrenia$209,375
R21 · FY2022 · MH
Endocannabinoid System Alterations in Opioid Use Disorder (OUD)$209,375
R21 · FY2022 · DA
Do hippocampal synaptic density deficits in cannabis use disorder improve following abstinence?$524,821
R01 · FY2021 · DA · contact PI
Preliminary studies of muscarinic M1 receptor availability and cognition in schizophrenia$251,250
R21 · FY2021 · MH
Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain.$0
I01 · FY2021 · VA · contact PI
Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD)$2,721,668
U01 · FY2019 · DA · contact PI
Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD)$2,727,105
U01 · FY2018 · DA · contact PI
CB1R Availability in Synthetic Psychoactive Cannabinoid Users$209,375
R21 · FY2018 · DA · contact PI
Synaptic Vesicle Density in Cannabis Dependence$209,375
R21 · FY2018 · DA · contact PI
Effects of Cannabis Exposure on Electrophysiological Markers of Brain Function in Adolescents$180,075
R21 · FY2018 · DA · contact PI
Characterization of Cannabinoid Induced Acute Persistent Psychosis (CIAPP)$162,592
R21 · FY2018 · DA · contact PI
Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD)$3,184,864
U01 · FY2017 · DA · contact PI
CB1R Availability in Synthetic Psychoactive Cannabinoid Users$251,250
R21 · FY2017 · DA · contact PI
Synaptic Vesicle Density in Cannabis Dependence$251,250
R21 · FY2017 · DA · contact PI
Effects of Cannabis Exposure on Electrophysiological Markers of Brain Function in Adolescents$216,090
R21 · FY2017 · DA · contact PI
Characterization of Cannabinoid Induced Acute Persistent Psychosis (CIAPP)$211,588
R21 · FY2017 · DA · contact PI
Intravenous Alcohol and THC Effects on Simulated Driving and Related Cognition$155,444
R21 · FY2016 · AA · contact PI
Intravenous Alcohol and THC Effects on Simulated Driving and Related Cognition$188,169
R21 · FY2015 · AA · contact PI
FAAH-Inhibitor for Cannabis Dependence$117,730
U01 · FY2015 · DA · contact PI
Ability of Partial Inverse Agonist, Iomazenil, to Block Ethanol Effects in Humans$0
I01 · FY2015 · VA · contact PI
FAAH-Inhibitor for Cannabis Dependence$502,103
U01 · FY2014 · DA · contact PI
Ability of Partial Inverse Agonist, Iomazenil, to Block Ethanol Effects in Humans$0
I01 · FY2014 · VA · contact PI
FAAH-Inhibitor for Cannabis Dependence$482,908
U01 · FY2013 · DA · contact PI
Imaging Brain Cannabinoid Receptors (CB1) in Schizophrenia$170,280
R21 · FY2013 · MH · contact PI
Ability of Partial Inverse Agonist, Iomazenil, to Block Ethanol Effects in Humans$0
I01 · FY2013 · VA · contact PI
FAAH-Inhibitor for Cannabis Dependence$519,077
U01 · FY2012 · DA · contact PI
Imaging Brain Cannabinoid Receptors (CB1) in Schizophrenia$212,850
R21 · FY2012 · MH · contact PI
Imaging Brain Cannabinoid Receptors in Cannabis Dependence, Withdrawal and Abstin$207,500
R21 · FY2012 · DA · contact PI
Cannabidiol Modulation of ???-9-THC???s Psychotomimetic Effects in Healthy Humans$163,625
R21 · FY2012 · DA
FAAH-Inhibitor for Cannabis Dependence$100,919
U01 · FY2012 · DA · contact PI
Ability of Partial Inverse Agonist, Iomazenil, to Block Ethanol Effects in Humans$0
I01 · FY2012 · VA · contact PI
Imaging Nicotinic Acetylcholine Receptors in Schizophrenia$280,210
R01 · FY2011 · DA · contact PI
Imaging Brain Cannabinoid Receptors in Cannabis Dependence, Withdrawal and Abstin$248,250
R21 · FY2011 · DA · contact PI
Cannabidiol Modulation of ???-9-THC???s Psychotomimetic Effects in Healthy Humans$196,350
R21 · FY2011 · DA
Imaging Nicotinic Acetylcholine Receptors in Schizophrenia$288,883
R01 · FY2010 · DA · contact PI
GABA Deficits and Vulnerability to Cannabinoid-Induced Psychosis$167,403
R21 · FY2010 · MH · contact PI
Imaging Nicotinic Acetylcholine Receptors in Schizophrenia$291,809
R01 · FY2009 · DA · contact PI
NEUROBIOLOGY OF CANNABIS EFFECTS$222,125
R01 · FY2009 · DA · contact PI
GABA Deficits and Vulnerability to Cannabinoid-Induced Psychosis$207,058
R21 · FY2009 · MH · contact PI
NEUROBIOLOGY OF CANNABIS EFFECTS$222,139
R01 · FY2008 · DA · contact PI
Cannabinoid Receptor Function in Alcoholism: Effects of D-9-THC$186,588
R21 · FY2008 · AA · contact PI
Cannabinoids, Neural Synchrony and Information Processing$159,005
R21 · FY2008 · DA · contact PI
NEUROBIOLOGY OF CANNABIS EFFECTS$225,991
R01 · FY2007 · DA · contact PI
Cannabinoids, Neural Synchrony and Information Processing$194,700
R21 · FY2007 · DA · contact PI
Cannabinoid Receptor Function in Alcoholism: Effects of D-9-THC$152,368
R21 · FY2007 · AA · contact PI
NEUROBIOLOGY OF CANNABIS BEHAVIORAL EFFECTS$202,465
R01 · FY2003 · DA
NEUROBIOLOGY OF CANNABIS BEHAVIORAL EFFECTS$198,009
R01 · FY2002 · DA
GLYCINE-KETAMINE INTERACTIONS IN HEALTHY SUBJECTS$129,164
R01 · FY2002 · MH
NEUROBIOLOGY OF CANNABIS BEHAVIORAL EFFECTS$194,290
R01 · FY2001 · DA
GLYCINE-KETAMINE INTERACTIONS IN HEALTHY SUBJECTS$129,164
R01 · FY2001 · MH
GLYCINE-KETAMINE INTERACTIONS IN HEALTHY SUBJECTS$127,746
R01 · FY2000 · MH